CO2023005188A2 - Compuestos y su uso en el tratamiento del cáncer - Google Patents
Compuestos y su uso en el tratamiento del cáncerInfo
- Publication number
- CO2023005188A2 CO2023005188A2 CONC2023/0005188A CO2023005188A CO2023005188A2 CO 2023005188 A2 CO2023005188 A2 CO 2023005188A2 CO 2023005188 A CO2023005188 A CO 2023005188A CO 2023005188 A2 CO2023005188 A2 CO 2023005188A2
- Authority
- CO
- Colombia
- Prior art keywords
- compounds
- cancer treatment
- treatment
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063085384P | 2020-09-30 | 2020-09-30 | |
| PCT/EP2021/076752 WO2022069520A1 (en) | 2020-09-30 | 2021-09-29 | Compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023005188A2 true CO2023005188A2 (es) | 2023-05-19 |
Family
ID=78085628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0005188A CO2023005188A2 (es) | 2020-09-30 | 2023-04-24 | Compuestos y su uso en el tratamiento del cáncer |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230374007A1 (enExample) |
| EP (1) | EP4221756A1 (enExample) |
| JP (1) | JP2023543299A (enExample) |
| KR (1) | KR20230079408A (enExample) |
| CN (1) | CN116249554A (enExample) |
| AU (2) | AU2021353968B2 (enExample) |
| BR (1) | BR112023005708A2 (enExample) |
| CA (1) | CA3195695A1 (enExample) |
| CL (1) | CL2023000881A1 (enExample) |
| CO (1) | CO2023005188A2 (enExample) |
| CR (1) | CR20230185A (enExample) |
| DO (1) | DOP2023000062A (enExample) |
| EC (1) | ECSP23030959A (enExample) |
| IL (1) | IL301626A (enExample) |
| MX (1) | MX2023003564A (enExample) |
| PE (1) | PE20230782A1 (enExample) |
| WO (1) | WO2022069520A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115141179B (zh) * | 2021-03-31 | 2024-09-13 | 江苏恒瑞医药股份有限公司 | 一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用 |
| US20250205344A1 (en) | 2022-03-24 | 2025-06-26 | Glaxosmithkline Intellectual Property Development Limited | 2,4-dioxotetrahydropyrimidinyl deratives as degrons in protacs |
| USD1018747S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
| USD1020957S1 (en) * | 2022-04-15 | 2024-04-02 | Puttshack LTD | Miniature golf hole |
| USD1018746S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
| USD1018676S1 (en) * | 2022-04-15 | 2024-03-19 | Puttshack LTD | Miniature golf hole |
| US20260098043A1 (en) * | 2022-09-14 | 2026-04-09 | Hainan Simcere Zaiming Pharmeceutical Co., Ltd. | Polycyclic compound and use thereof |
| TW202508568A (zh) | 2023-04-07 | 2025-03-01 | 瑞典商阿斯特捷利康公司 | Ｉｒａｋ４蛋白水解靶向嵌合體 |
| PE20260301A1 (es) | 2023-06-14 | 2026-02-10 | Astrazeneca Ab | Derivados de 3-[3-amino-6-(2-hidroxifenil)piridazin-4-il]-3,8-diazabiciclo[3.2.1]octano como protacs degradantes de smarca2 para el tratamiento del cancer |
| PE20260307A1 (es) * | 2023-06-14 | 2026-02-11 | Astrazeneca Ab | Degradadores de smarca2 y usos de estos |
| CN121773112A (zh) * | 2023-08-17 | 2026-03-31 | 海思科医药集团股份有限公司 | 一种氰基芳香环衍生物及其在医药上的应用 |
| TW202530192A (zh) | 2023-09-22 | 2025-08-01 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 新穎化合物 |
| CN117430605A (zh) * | 2023-10-26 | 2024-01-23 | 广西天铭药业有限公司 | 一种kras g12c抑制剂amg-510中间体的合成方法 |
| WO2025114875A1 (en) * | 2023-12-01 | 2025-06-05 | Astrazeneca Ab | Er degraders and uses thereof |
| WO2025125575A1 (en) | 2023-12-14 | 2025-06-19 | Astrazeneca Ab | Irak4 protacs |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0422263D0 (en) | 2004-10-07 | 2004-11-10 | Glaxo Group Ltd | Novel compounds |
| AU2011239966B2 (en) | 2010-04-16 | 2014-05-08 | Ac Immune S.A. | Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins |
| WO2014210255A1 (en) | 2013-06-26 | 2014-12-31 | Abbvie Inc. | Primary carboxamides as btk inhibitors |
| JP2017528498A (ja) | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| IL312367A (en) * | 2017-01-31 | 2024-06-01 | Arvinas Operations Inc | Cereblon ligands and bifunctional compounds comprising the same |
| WO2019057757A1 (en) * | 2017-09-20 | 2019-03-28 | Astrazeneca Ab | 1,3-DIHYDROIMIDAZO [4,5-C] CINNOLIN-2-ONE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| CN120698983A (zh) * | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
-
2021
- 2021-09-29 CA CA3195695A patent/CA3195695A1/en active Pending
- 2021-09-29 CR CR20230185A patent/CR20230185A/es unknown
- 2021-09-29 PE PE2023001220A patent/PE20230782A1/es unknown
- 2021-09-29 EP EP21787317.3A patent/EP4221756A1/en active Pending
- 2021-09-29 AU AU2021353968A patent/AU2021353968B2/en active Active
- 2021-09-29 CN CN202180065971.2A patent/CN116249554A/zh active Pending
- 2021-09-29 MX MX2023003564A patent/MX2023003564A/es unknown
- 2021-09-29 WO PCT/EP2021/076752 patent/WO2022069520A1/en not_active Ceased
- 2021-09-29 IL IL301626A patent/IL301626A/en unknown
- 2021-09-29 BR BR112023005708A patent/BR112023005708A2/pt unknown
- 2021-09-29 US US18/247,014 patent/US20230374007A1/en active Pending
- 2021-09-29 JP JP2023519522A patent/JP2023543299A/ja active Pending
- 2021-09-29 KR KR1020237014514A patent/KR20230079408A/ko active Pending
-
2023
- 2023-03-24 DO DO2023000062A patent/DOP2023000062A/es unknown
- 2023-03-27 CL CL2023000881A patent/CL2023000881A1/es unknown
- 2023-04-24 CO CONC2023/0005188A patent/CO2023005188A2/es unknown
- 2023-04-27 EC ECSENADI202330959A patent/ECSP23030959A/es unknown
-
2025
- 2025-01-09 AU AU2025200137A patent/AU2025200137A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021353968B2 (en) | 2024-10-10 |
| BR112023005708A2 (pt) | 2023-05-02 |
| WO2022069520A1 (en) | 2022-04-07 |
| AU2025200137A1 (en) | 2025-01-30 |
| MX2023003564A (es) | 2023-04-04 |
| DOP2023000062A (es) | 2023-05-31 |
| KR20230079408A (ko) | 2023-06-07 |
| AU2021353968A1 (en) | 2023-06-08 |
| CR20230185A (es) | 2023-06-27 |
| AU2021353968A9 (en) | 2024-10-03 |
| ECSP23030959A (es) | 2023-05-31 |
| CA3195695A1 (en) | 2022-04-07 |
| CL2023000881A1 (es) | 2023-11-17 |
| US20230374007A1 (en) | 2023-11-23 |
| PE20230782A1 (es) | 2023-05-09 |
| IL301626A (en) | 2023-05-01 |
| JP2023543299A (ja) | 2023-10-13 |
| CN116249554A (zh) | 2023-06-09 |
| EP4221756A1 (en) | 2023-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023005188A2 (es) | Compuestos y su uso en el tratamiento del cáncer | |
| DOP2021000198A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| CR20210552A (es) | Inhibidores del inflamasoma nlrp3 | |
| MX2020006438A (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1. | |
| NI202000099A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
| CO2022014073A2 (es) | Compuestos antivirales y métodos para la administración de los mismos | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| CO6382119A2 (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| CO2018004933A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
| NI201900094A (es) | COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
| EP4635494A3 (en) | AMIDO HETERO-ROMATIC COMPOUNDS | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| CR20170546A (es) | Derivados de imidazo[1,2-b][1,2,4]triazina como agentes antiparasitarios | |
| MX385289B (es) | Formas sólidas del inhibidor de la tirosina treonina cinasa (ttk). |